Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy.

ABSTRACT: In recent decades, adoptive cell transfer and checkpoint blockade therapies have revolutionized immunotherapeutic approaches to cancer treatment. Advances in whole exome/genome sequencing and bioinformatic detection of tumour-specific genetic variations and the amino acid sequence alterations they induce have revealed that T cell mediated anti-tumour immunity is substantially directed at mutated peptide sequences, and the identification and therapeutic targeting of patient-specific mutated peptide antigens now represents an exciting and rapidly progressing frontier of personalized medicine in the treatment of cancer. This review outlines the historical identification and validation of mutated peptide neoantigens as a target of the immune system, and the technical development of bioinformat

SUBMITTER: Verdon DJ 

PROVIDER: S-EPMC8391927 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature